0001562180-17-003064.txt : 20170929
0001562180-17-003064.hdr.sgml : 20170929
20170929182242
ACCESSION NUMBER: 0001562180-17-003064
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170929
FILED AS OF DATE: 20170929
DATE AS OF CHANGE: 20170929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEFKOFF KYLE
CENTRAL INDEX KEY: 0001191818
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16633
FILM NUMBER: 171112745
MAIL ADDRESS:
STREET 1: 3200 WALNUT ST
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARRAY BIOPHARMA INC
CENTRAL INDEX KEY: 0001100412
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841460811
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 3200 WALNUT STREET
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 3033816600
MAIL ADDRESS:
STREET 1: 3200 WALNUT STREET
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2017-09-29
false
0001100412
ARRAY BIOPHARMA INC
ARRY
0001191818
LEFKOFF KYLE
C/O BOULDER VENTURES
1941 PEARL STREET, SUITE 300
BOULDER
CO
80302
true
false
false
false
Common Stock
2017-09-29
4
M
false
45000.00
10.58
A
51585.00
D
Common Stock
2017-09-29
4
S
false
38865.00
12.31
D
12720.00
D
Common Stock
45000.00
I
See footnote
Stock Option
10.58
2017-09-29
4
M
false
45000.00
0.00
D
2010-11-01
2017-11-01
Common Stock
45000.00
0.00
D
This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price.
Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.
The option vested in 3 equal annual installments beginning on November 1, 2008.
Jason Haddock, attorney-in-fact for Lefkoff Kyle
2017-09-29
EX-24
2
kylelefkoffpoa.txt
POA
Power of Attorney
The undersigned constitutes and appoints John R. Moore and Jason Haddock, and
each of them, as his true and lawful attorney-in-fact and agent, with the full
power of substitution and resubstitution, from the undersigned and in the
undersigned and in the undersigned's behalf of all Forms 3, 4 and 5 (including)
any amendments thereto) that the undersigned may be required to file with the
U.S. Securities and Exchange Commission as a result of the undersigned's
ownership of or transactions in securities of Array BioPharma Inc. The Authority
of John R. Moore and Jason Haddock under this statement shall continue until the
undersigned is no longer required to file Forms 3, 4 and 5 with regard to the
undersigned's ownership of or transactions in securities of Array BioPharma Inc
unless earlier revoked in writing. The undersigned acknowledges that neither
John R. Moore nor Jason Haddock is assuming any of the undersigned's
responsibilities to comply with Section 16 of the Section 16 of the Securities
Exchange Act of 1934.
Dated: April 27, 2017
/s/ Kyle Lefkoff